IDEAS home Printed from https://ideas.repec.org/a/plo/pmed00/1002847.html
   My bibliography  Save this article

Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network

Author

Listed:
  • Andrée-Anne Grosset
  • Véronique Ouellet
  • Christine Caron
  • Gabriela Fragoso
  • Véronique Barrès
  • Nathalie Delvoye
  • Mathieu Latour
  • Armen Aprikian
  • Alain Bergeron
  • Simone Chevalier
  • Ladan Fazli
  • Neil Fleshner
  • Martin Gleave
  • Pierre Karakiewicz
  • Louis Lacombe
  • Jean-Baptiste Lattouf
  • Theodorus van der Kwast
  • Dominique Trudel
  • Anne-Marie Mes-Masson
  • Fred Saad
  • for the Canadian Prostate Cancer Biomarker Network

Abstract

Background: The identification of patients with high-risk prostate cancer (PC) is a major challenge for clinicians, and the improvement of current prognostic parameters is an unmet clinical need. We and others have identified an association between the nuclear localization of NF-κB p65 and biochemical recurrence (BCR) in PC in small and/or single-centre cohorts of patients. Methods and findings: In this study, we accessed 2 different multi-centre tissue microarrays (TMAs) representing cohorts of patients (Test-TMA and Validation-TMA series) of the Canadian Prostate Cancer Biomarker Network (CPCBN) to validate the association between p65 nuclear frequency and PC outcomes. Immunohistochemical staining of p65 was performed on the Test-TMA and Validation-TMA series, which include PC tissues from patients treated by first-line radical prostatectomy (n = 250 and n = 1,262, respectively). Two independent observers evaluated the p65 nuclear frequency in digital images of cancer tissue and benign adjacent gland tissue. Kaplan–Meier curves coupled with a log-rank test and univariate and multivariate Cox regression models were used for statistical analyses of continuous values and dichotomized data (cutoff of 3%). Multivariate analysis of the Validation-TMA cohort showed that p65 nuclear frequency in cancer cells was an independent predictor of BCR using continuous (hazard ratio [HR] 1.02 [95% CI 1.00–1.03], p = 0.004) and dichotomized data (HR 1.33 [95% CI 1.09–1.62], p = 0.005). Using a cutoff of 3%, we found that this biomarker was also associated with the development of bone metastases (HR 1.82 [95% CI 1.05–3.16], p = 0.033) and PC-specific mortality (HR 2.63 [95% CI 1.30–5.31], p = 0.004), independent of clinical parameters. BCR-free survival, bone-metastasis-free survival, and PC-specific survival were shorter for patients with higher p65 nuclear frequency (p

Suggested Citation

  • Andrée-Anne Grosset & Véronique Ouellet & Christine Caron & Gabriela Fragoso & Véronique Barrès & Nathalie Delvoye & Mathieu Latour & Armen Aprikian & Alain Bergeron & Simone Chevalier & Ladan Fazli &, 2019. "Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network," PLOS Medicine, Public Library of Science, vol. 16(7), pages 1-15, July.
  • Handle: RePEc:plo:pmed00:1002847
    DOI: 10.1371/journal.pmed.1002847
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002847
    Download Restriction: no

    File URL: https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002847&type=printable
    Download Restriction: no

    File URL: https://libkey.io/10.1371/journal.pmed.1002847?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pmed00:1002847. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosmedicine (email available below). General contact details of provider: https://journals.plos.org/plosmedicine/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.